Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation
2002

Cimetidine's Effects on Liver Cancer in Mice

Sample size: 38 publication 10 minutes Evidence: moderate

Author Information

Author(s): Caballero F, Gerez E, Batlle A, Vazquez E

Primary Institution: Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP)

Hypothesis

Cimetidine can prevent or reverse metabolic alterations caused by the carcinogen p-dimethylaminoazobenzene.

Conclusion

Cimetidine treatment partially prevented and reversed some metabolic changes induced by a carcinogen, but did not restore liver damage or oxidative stress.

Supporting Evidence

  • Cimetidine reduced cytochrome P450 levels by 40%.
  • Cimetidine restored ALA-S activity to baseline levels.
  • Cimetidine did not affect catalase activity in treated animals.
  • Lipid peroxidation levels remained high despite cimetidine treatment.
  • Glutathione S-transferase activity increased significantly with carcinogen treatment.

Takeaway

Cimetidine is a drug that can help protect mice from some harmful effects of a cancer-causing substance, but it doesn't fix all the damage.

Methodology

Male CF1 mice were divided into groups and treated with p-dimethylaminoazobenzene and cimetidine, with various assays conducted to measure enzyme activities and liver damage.

Potential Biases

Potential bias in animal model selection and treatment protocols.

Limitations

The study did not assess long-term effects of cimetidine or its impact on all metabolic pathways involved in liver damage.

Participant Demographics

Male CF1 mice, average weight 30g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600102

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication